Suggested remit: To appraise the clinical and cost effectiveness of epcoritamab within its marketing authorisation for relapsed or refractory follicular lymphoma.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6338

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6338 13 November 2024 - 11 December 2024

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 November 2024 In progress. Scoping commencing
07 November 2024 Please note that this appraisal has been scheduled back into the work programme to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early February 2025 when we will write to you about how you can get involved.
11 June 2024 Suspended. The company has requested a delay to the evidence submission for this appraisal, therefore we will be terminating this topic ID number in line with receipt of the MA and a new topic ID will be scheduled and communicated to stakeholders.
29 February 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early August 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
20 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual